Cue Biopharma, Inc. (CUE)

NCM – Real Time Price. Currency in USD

27.66

-0.58 (-2.05%)

Market open: Aug 12, 2026, 1:00 PM EDT

29.82

+1.58 (5.61%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

03.08.2026

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.

Videos

No Data

There is no data to display

Press releases

03.08.2026

Cue Biopharma, Inc. (CUE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cue Biopharma, Inc. (CUE)

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Videos

No Data

Press releases

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Videos

No Data

Press releases

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Search stocks

Cue Biopharma, Inc. (CUE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cue Biopharma, Inc. (CUE)

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Videos

No Data

Press releases

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Videos

No Data

Press releases

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission